- likes
- 328
- comments
- 8
Post
Obstructive sleep apnea (OSA) is a common and often undertreated contributor to cardiovascular risk. In the Phase 3 ATTAIN-OSA trial, our GLP-1 pill significantly reduced the apnea-hypopnea index (AHI) and improved key cardiovascular risk factors in adults with moderate-to-severe OSA and obesity. These results, presented today at the American Heart Association’s #ScientificSessions26, show our GLP-1 pill could help treat conditions that increase risk of heart disease. Read more: https://lnkd.in/emMmNHqx